동물 모델 시장 : 동물 유형별, 모델 유형별, 용도, 최종 사용자별 - 세계 예측(2026-2032년)

The Animal Model Market was valued at USD 3.42 billion in 2025 and is projected to grow to USD 3.68 billion in 2026, with a CAGR of 8.27%, reaching USD 5.98 billion by 2032.

A comprehensive introduction outlining how scientific progress, ethical imperatives, and regulatory expectations converge to redefine preclinical animal model strategies

The contemporary animal model landscape sits at the intersection of rapid scientific innovation, stringent ethical expectations, and evolving regulatory oversight. Preclinical investigators and organizational leaders must navigate an increasingly complex environment where advances in gene editing, improvements in husbandry and model characterization, and heightened reproducibility standards collectively influence decision-making. As research institutions, pharmaceutical developers, and service providers adapt, the demand for clarity around model selection, operational resilience, and compliance has become central to sustaining translational pipelines.

Across this environment, stakeholders are placing greater emphasis on validated disease models and genetically engineered systems to increase translational relevance while simultaneously responding to external pressures to refine animal use and enhance welfare. This dynamic requires a nuanced understanding of model capabilities and limitations, as well as strategies for integrating alternative technologies where appropriate. Consequently, the ability to align scientific objectives with operational structures, vendor ecosystems, and regulatory expectations is now a critical determinant of project success and ethical stewardship.

How gene editing, welfare-driven governance, and digital integration are jointly transforming model development, validation practices, and collaborative research frameworks

Significant transformative shifts are reshaping how animal models are developed, validated, and deployed across biomedical research. Advances in precision gene editing, particularly CRISPR-based approaches, are accelerating the creation of highly specific genetically engineered models that better recapitulate human disease biology, thereby changing the calculus for model selection and experimental design. At the same time, improvements in phenotype characterization and in vivo imaging are enhancing longitudinal study capabilities and reducing the number of animals required for robust endpoints, which in turn affects resource allocation and study timelines.

Concurrently, ethical and regulatory landscapes are exerting stronger influence over experimental practice. Institutions and sponsors are strengthening governance frameworks to align with international 3Rs principles, resulting in more rigorous welfare monitoring and justification for animal use. In response, service providers and internal teams are increasingly investing in welfare-positive housing, enrichment programs, and staff training to meet both ethical expectations and scientific quality goals. In parallel, digital transformation and data integration-encompassing laboratory information management systems, standardized metadata practices, and machine learning-enabled analytics-are improving reproducibility and enabling more rapid cross-study comparisons. These combined shifts are driving a migration toward collaborative networks of specialized providers, centralized model repositories, and multidisciplinary teams that can deliver higher-confidence translational outputs.

Implications of evolving US trade measures for preclinical supply chains, procurement resilience, and cross-border collaboration preparedness in 2025

Policy interventions and tariff adjustments in the United States projected for 2025 are introducing new considerations for preclinical supply chains and cross-border collaborations. Trade measures that affect the import and export of specialized biological materials, custom reagents, and equipment can influence procurement lead times and vendor selection decisions. As a result, organizations that rely on international suppliers for genetically engineered lines, breeding stock, or specialized consumables may need to reassess sourcing strategies to mitigate the operational impact of elevated import compliance scrutiny and potential cost reallocation.

In practical terms, these trade dynamics are prompting greater attention to supplier diversification, onshoring of critical production capabilities, and regionalization of supply chains where feasible. Organizations are emphasizing contractual protections, enhanced inventory planning, and multi-supplier qualification to ensure continuity of studies and reduce exposure to policy-driven disruptions. Moreover, the tariffs dialogue is catalyzing conversations between industry stakeholders and regulatory authorities about harmonizing standards for material transfer, quarantine, and documentation to minimize administrative friction. Ultimately, the implication for research programs is a need to integrate trade policy risk into project timelines and procurement governance so that scientific objectives remain resilient in the face of shifting cross-border rules.

Actionable segmentation intelligence revealing how species selection, model construction, application focus, and end-user profiles create differentiated operational and scientific priorities

Segmentation insights reveal how distinct animal types, model constructs, application areas, and end users shape heterogeneous demands and strategic priorities across the preclinical ecosystem. The animal type dimension differentiates Nonrodents and Rodents, where Nonrodents encompass species such as Dogs, Nonhuman Primates, and Rabbits, and Rodents include Hamsters & Guinea Pigs, Mice, and Rats; this biological diversity drives variation in regulatory oversight, housing requirements, and translational applicability. Therefore, decisions about species selection are increasingly informed by the balance between physiological relevance and operational considerations such as breeding cycles, housing footprint, and welfare protocols.

Model type granularity further layers complexity: Disease Models, Genetically Engineered Models, Pharmacological Models, and Surgical Models each serve distinct experimental purposes. Within genetically engineered approaches, subdivisions such as CRISPR Models, Knock-In Models, Knockout Models, and Transgenic Models differ in their technical construction and applicability for target validation, mechanistic studies, and therapeutic testing. These differences influence not only experimental design but also validation pathways and reproducibility expectations, leading organizations to develop tailored standard operating procedures and characterization pipelines for each model class.

Applications span ADME & PK Studies, Disease Research, Drug Discovery & Development, and Toxicology Assessment, and each application imposes unique fidelity requirements, endpoint selection, and data provenance needs. For instance, ADME and pharmacokinetic investigations prioritize controlled physiology and precise sampling, whereas disease research may require complex phenotyping and longitudinal outcome measures. As a result, operational investments in assay platforms, imaging modalities, and bioanalytical capacity are frequently aligned to the dominant application portfolio of an organization.

End users range from Academic & Research Institutes to Contract Research Organizations, Hospitals & Diagnostic Laboratories, and Pharmaceutical & Biotechnology Companies, each bringing different procurement behaviors, regulatory responsibilities, and timelines. Academic labs often prioritize exploratory flexibility and open science practices, while contract research organizations focus on scalable, validated workflows that meet sponsor requirements. Clinical laboratories and health systems integrate preclinical insights into translational pathways and diagnostic development, and industry partners require robust model justification to support regulatory submissions. Recognizing these segmentation-driven differences enables stakeholders to align model selection, vendor partnerships, and governance frameworks with the specific needs of their primary end-user constituencies.

Regional analysis highlighting how the Americas, Europe Middle East & Africa, and Asia-Pacific each influence sourcing, compliance, and collaborative research strategies

Regional dynamics are shaping how organizations approach animal model sourcing, regulatory compliance, and collaboration strategies across key geographies. The Americas continue to be a hub for therapeutic innovation and contract research activity, with dense networks of academic institutions and commercial sponsors that drive demand for characterized models and specialized services. This concentration of capability supports robust translational programs, yet it also elevates competition for talent, infrastructure, and laboratory space, encouraging strategic alliances and shared-resource models to optimize throughput.

Europe, Middle East & Africa present a mosaic of regulatory frameworks and ethical norms that influence model development and cross-border exchanges. Many jurisdictions in this region emphasize stringent welfare standards and harmonized oversight, which in turn shape vendor certification practices and study design expectations. Additionally, collaborative pan-regional consortia and public-private partnerships play a notable role in pooling resources for large-scale preclinical initiatives and in advancing standardized model validation criteria.

Asia-Pacific has emerged as a dynamic region for both service provision and model innovation, with rapid investment in gene editing capacity, breeding infrastructure, and contract research capabilities. Diverse regulatory approaches across countries create opportunities for regional specialization, while increasing local scientific expertise is fostering indigenous model development and translational research programs. Together, these regional patterns highlight the importance of tailoring sourcing strategies, compliance roadmaps, and partnership approaches to the specific risks and advantages present within each geography.

Strategic company behaviors and partnership models that drive competitive differentiation through specialization, data integration, and regulatory-aligned service offerings

Key company behaviors in the animal model ecosystem reflect strategic prioritization around specialization, vertical integration, and collaborative service delivery. Leading providers are investing in high-fidelity genetically engineered capabilities and robust breeding programs to offer differentiated model portfolios, while many service firms are expanding their analytics and bioinformatics layers to add value beyond animal production. This trend toward bundling technical services with deeper data interpretation aims to reduce translational gaps and to provide sponsors with more actionable insights from preclinical programs.

Another notable direction is the consolidation of capabilities through partnerships and alliances, enabling organizations to combine operational strengths-such as vivarium management, regenerative medicine expertise, or in vivo imaging-into comprehensive service offerings. At the same time, some providers are pursuing modular, outsourced arrangements that allow sponsors to access specific competencies without committing to full-scale integration. Across these strategies, investment in regulatory intelligence, quality management systems, and welfare accreditation is common, as customers increasingly demand demonstrable standards and traceability across the supply chain. These company-level choices influence competitive positioning, client retention, and the evolution of service-level expectations across the sector.

Practical and prioritized strategic recommendations for research leaders to enhance model fidelity, fortify supply chains, and elevate welfare compliance while accelerating translational outcomes

Industry leaders should adopt a proactive mix of scientific investment, supply chain resilience, and governance enhancements to capitalize on current opportunities and mitigate emerging risks. First, embedding advanced genetically engineered model capabilities-especially CRISPR-enabled platforms and comprehensive phenotyping workflows-will improve target validation and reduce downstream translational uncertainty. Complementing this, organizations should formalize model characterization standards and establish cross-functional review processes that ensure reproducibility and defendable scientific rationale.

Second, supply chain strategies must evolve to reduce exposure to trade policy shifts and supply interruptions. This involves diversifying vendor relationships, qualifying regional suppliers, and developing contingency inventories for mission-critical materials. In addition, investing in localized breeding capacity or regional partnerships can shorten lead times and provide operational buffers during periods of commerce volatility. Third, companies should elevate welfare and compliance governance by integrating enhanced monitoring technologies, independent audits, and staff competency programs that align with evolving ethical expectations and regulatory scrutiny.

Finally, leaders should leverage data science and digital platforms to achieve higher experimental efficiency. Standardizing metadata capture, adopting interoperable laboratory systems, and deploying machine learning for endpoint prediction will increase reproducibility and support faster decision cycles. Combined, these actions enhance scientific credibility, operational stability, and stakeholder trust, positioning organizations to sustain translational momentum while remaining responsive to policy and ethical imperatives.

Robust multi-source research methodology combining expert consultations, systematic literature synthesis, and iterative validation to ensure defensible and actionable insights

The research methodology underpinning this analysis leverages a layered approach that synthesizes primary qualitative insights with structured secondary validation. Primary inputs include consultations with subject-matter experts across preclinical research, veterinary sciences, and regulatory affairs to capture nuanced operational realities and emerging scientific trends. These interviews were supplemented by a systematic review of peer-reviewed literature, technical guidance documents, and recognized standards to contextualize technological advances and welfare practices.

Data triangulation ensured robustness by cross-referencing expert perspectives with publicly available technical reports and documented policy changes. Wherever applicable, methodological transparency was maintained through clear documentation of inclusion criteria, definitions for model classes, and the provenance of technical assertions. Ethical considerations guided the process throughout, with respect for data privacy and professional confidentiality in all expert engagements. This multi-source, iterative approach supports a defensible interpretation of sector dynamics and yields insights tailored to decision-makers requiring both operational guidance and scientific credibility.

A conclusive synthesis emphasizing the need to integrate scientific precision, ethical governance, and supply chain resilience to sustain translational success

In conclusion, the animal model landscape is entering a period of refined specialization, heightened ethical accountability, and operational recalibration. Scientific advances-especially in gene editing and phenotype characterization-are improving the translational precision of models, while at the same time regulators and stakeholders are raising the bar for welfare and reproducibility. These concurrent forces require organizations to be deliberate in model selection, to strengthen supply chain agility, and to invest in data and governance infrastructures that support reliable translational outcomes.

Looking forward, success will depend on the ability to integrate technological capabilities with responsible stewardship and pragmatic operational planning. Organizations that proactively align their scientific agendas with resilient procurement practices and transparent welfare governance will be better positioned to deliver high-quality preclinical evidence and to respond to policy or market shifts with agility.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Model Market, by Animal Type

• 8.1. Nonrodents
  • 8.1.1. Dogs
  • 8.1.2. Nonhuman Primates
  • 8.1.3. Rabbits
• 8.2. Rodents
  • 8.2.1. Hamsters & Guinea Pigs
  • 8.2.2. Mice
  • 8.2.3. Rats

9. Animal Model Market, by Model Type

• 9.1. Disease Models
• 9.2. Genetically Engineered Models
  • 9.2.1. CRISPR Models
  • 9.2.2. Knock-In Models
  • 9.2.3. Knockout Models
  • 9.2.4. Transgenic Models
• 9.3. Pharmacological Models
• 9.4. Surgical Models

10. Animal Model Market, by Application

• 10.1. ADME & PK Studies
• 10.2. Disease Research
• 10.3. Drug Discovery & Development
• 10.4. Toxicology Assessment

11. Animal Model Market, by End User

• 11.1. Academic & Research Institutes
• 11.2. Contract Research Organizations
• 11.3. Hospitals & Diagnostic Laboratories
• 11.4. Pharmaceutical & Biotechnology Companies

12. Animal Model Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Animal Model Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Animal Model Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Animal Model Market

16. China Animal Model Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Aurora BioSolutions
• 17.6. Biocytogen
• 17.7. Charles River Laboratories International Inc.
• 17.8. Crown Bioscience Inc.
• 17.9. Cyagen Biosciences Inc.
• 17.10. Envigo RMS LLC
• 17.11. Genoway
• 17.12. Hera BioLabs
• 17.13. ingenious targeting laboratory
• 17.14. Inotiv
• 17.15. Janvier Labs
• 17.16. Mirimus Inc.
• 17.17. Ozgene Pty Ltd
• 17.18. PhoenixBio Co. Ltd.
• 17.19. PolyGene AG
• 17.20. Taconic Biosciences Inc.
• 17.21. The Jackson Laboratory
• 17.22. Transgenic Inc.